Cargando…

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

PURPOSE: Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed. METHODS: To identify potential resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tracey, Natasha, Creedon, Helen, Kemp, Alain J., Culley, Jayne, Muir, Morwenna, Klinowska, Teresa, Brunton, Valerie G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997276/ https://www.ncbi.nlm.nih.gov/pubmed/31705351 http://dx.doi.org/10.1007/s10549-019-05489-1

Ejemplares similares

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer
por: Creedon, Helen, et al.
Publicado: (2016)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
por: Reix, Nathalie, et al.
Publicado: (2016)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
por: Liu, Yuanyuan, et al.
Publicado: (2019)

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
por: Creedon, Helen, et al.
Publicado: (2016)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
por: Bilous, Michael, et al.
Publicado: (2012)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
por: Sadanandam, Anguraj, et al.
Publicado: (2012)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
por: Tiainen, Satu, et al.
Publicado: (2020)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
por: Wu, Yanyuan, et al.
Publicado: (2017)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
por: Sui, Lin, et al.
Publicado: (2023)

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
por: Jääskeläinen, Minna M., et al.
Publicado: (2023)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Abstract 5 Human Umbilical Cord Blood-Derived Cell Therapy Product, DUOC-01, Promotes Remyelination by Driving the Differentiation of Oligodendrocyte Progenitor Cells
por: Xu, Li, et al.
Publicado: (2022)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs
por: Blyth, Karen, et al.
Publicado: (2016)

The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines
por: Haas, Markus, et al.
Publicado: (2022)

Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models
por: Trendowski, Matthew, et al.
Publicado: (2015)

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
por: Collery, Philippe, et al.
Publicado: (2015)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesis
por: Vanden Heuvel, John P., et al.
Publicado: (2015)

Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration
por: Trendowski, Matthew, et al.
Publicado: (2015)

Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma
por: Kyriakou, Sotiris, et al.
Publicado: (2019)

Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients
por: Lattimore, Vanessa, et al.
Publicado: (2020)

Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro
por: Trendowski, Matthew, et al.
Publicado: (2015)

The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines
por: Kucinska, Malgorzata, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5mb2pu49f8qoeu2vd98ef2amit